Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial

Dickran Kazandjian*, Neha Korde, Sham Mailankody, Elizabeth Hill, William D. Figg, Mark Roschewski, Ola Landgren

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

32 Scopus citations
Original languageEnglish
Pages (from-to)1781-1783
Number of pages3
JournalJAMA Oncology
Volume4
Issue number12
DOIs
StatePublished - Dec 2018
Externally publishedYes

Fingerprint

Dive into the research topics of 'Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial'. Together they form a unique fingerprint.

Cite this